Detalles de la búsqueda
1.
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(4): 496-508, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26968357
2.
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
N Engl J Med
; 354(6): 567-78, 2006 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-16467544
3.
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
J Clin Oncol
; 23(24): 5578-87, 2005 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16009949
4.
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Blood Cancer J
; 7(12): 644, 2017 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29238044
5.
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Anticancer Drugs
; 17(5): 587-95, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16702817
6.
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
J Clin Oncol
; 24(30): 4914-21, 2006 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17050875
7.
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.
Cancer
; 94(1): 25-36, 2002 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11815957
Resultados
1 -
7
de 7
1
Próxima >
>>